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31 Abstract
2 Objective: Schizophrenia is associated with a large cognitive impairment that is widely 
3 believed to remain stable after illness onset. Yet, even to date, 10-year prospective studies 
4 of cognitive functioning following the first episode with good methodology are rare. We 
5 examined whether schizophrenia patients experience cognitive decline following the first 
6 episode, whether this decline is generalized or confined to individual neuropsychological 
7 functions, and whether decline is specific to schizophrenia. 
8 Method: Participants were from a population-based, case-control study of patients with first-
9 episode psychosis that were followed prospectively up to 10 years post first admission. A 
10 neuropsychological battery was administered at index presentation and at follow-up to 
11 patients with a diagnosis of schizophrenia (n=65), or other psychoses (n=41), as well as to 
12 healthy comparison subjects (n=103). 
13 Results: The schizophrenia group exhibited declines in IQ and in measures of verbal 
14 knowledge, and memory, but not processing speed or executive functions. Processing 
15 speed and executive function impairments were already present at the first episode and 
16 remained stable thereafter. Magnitude of declines ranged between 0.28 and 0.66 standard 
17 deviations. Decline in measures of memory was not specific to schizophrenia and was also 
18 apparent in the group of patients with other psychoses. Healthy individuals with low IQ, on 
19 the other hand, showed no evidence of decline, suggesting that a decline is specific to 
20 psychosis.
21 Conclusions: Patients with schizophrenia and other psychoses experience cognitive 
22 decline after illness onset, but the magnitude of decline varies across cognitive functions. 
23 Distinct mechanisms consequent upon the illness and/or psychosocial factors may underlie 
24 impairments across different cognitive functions.  
425 Introduction
26 Cognitive impairment is a core feature of schizophrenia(1, 2). Understanding the nature and 
27 course of this impairment may have important implications for our understanding of the 
28 pathophysiology of the disorder.
29 Research has shown that individuals diagnosed with schizophrenia experience cognitive 
30 decline from the premorbid to post-onset period. There is clear evidence for moderate 
31 cognitive deficits in children and adolescents who later develop schizophrenia, with meta-
32 analyses showing an average premorbid deficit equal to 8 IQ points (0.5 Standard Deviation 
33 (SD))(3, 4). Cognitive deficits in adults diagnosed with schizophrenia are more pronounced, 
34 with meta-analyses reporting a 14-point IQ deficit (0.90 SD) in first-episode schizophrenia 
35 patients (5) and 15- to 21-point IQ deficits (1.0 to 1.5 SD) in chronic schizophrenia patients 
36 (1, 6, 7). In line with cross-sectional evidence, longitudinal studies of cognitive change in 
37 schizophrenia from before to after illness onset have shown evidence for cognitive decline 
38 (8). Three population-based studies have reported cognitive declines ranging from 6 to 12 IQ 
39 points (0.4 – 0.8 SD) between childhood and adulthood in individuals later diagnosed with 
40 schizophrenia (8-10).
41 Despite evidence for cognitive decline from before to after illness onset, the course of 
42 cognitive decline in schizophrenia remains unclear. While it is widely believed that cognitive 
43 impairments stabilize after illness onset (11-13), at least until older adult life (12, 14), few 
44 longitudinal studies have examined cognitive change from illness onset through to a decade 
45 later (sTable 1), and findings across studies and cognitive domains are mixed. Studies have 
46 reported a stabilization of the cognitive deficits, cognitive decline, as well as amelioration of 
47 cognitive functioning (sTable 1 and ref # (15)). 
48 Previous studies have been unable to comprehensively chart the course of cognitive deficits 
49 for several reasons. First, the majority of studies have used clinical samples, which may not 
50 be fully representative of the population of individuals with schizophrenia (8). Second, most 
51 studies followed participants for only 1 to 3 years from illness onset (sTable 1). We 
52 previously reported a slow, gradual increase in premorbid cognitive deficits, with losses 
53 equal to between 0.5 and 1 IQ point per year (16). Studies with short follow-ups, therefore, 
54 may be underpowered to capture decline. Third, few studies have included comparison 
55 groups, and therefore have not considered the potential impact of normative age-associated 
56 changes in cognitive functioning, which is necessary to rigorously test for cognitive change. 
57 Since, brain maturation continues into the third decade of life (17), previous estimates of the 
58 magnitude of cognitive decline may be biased. Finally, few studies have examined the effect 
559 of medication on cognitive functioning, and yet recent findings suggest that antipsychotic 
60 medications may contribute to the severity of cognitive decline (18).
61 In a previous report on this population-based, case-control study, we provided evidence for 
62 an IQ deficit, as well as varying degrees of impairment across individual cognitive domains 
63 following the first psychiatric diagnosis of schizophrenia (19). Study participants have since 
64 been followed-up and underwent neuropsychological testing a second time. Using identical 
65 neuropsychological measures at first assessment and follow-up, we were able to directly 
66 examine change in IQ and in individual cognitive functions after the first episode. To provide 
67 an accurate estimate of cognitive change over time, we compared patients to the healthy 
68 comparison subjects in the study followed during the same period. We tested three 
69 hypotheses. First, we examined the “IQ decline” hypothesis to establish whether 
70 schizophrenia patients exhibit a static IQ deficit or IQ decline. Second, we tested the 
71 “generalized decline” hypothesis to determine whether decline occurs across multiple 
72 cognitive domains, namely verbal knowledge, memory, language, processing speed, 
73 executive function/working memory and visuospatial ability. Finally, we tested the 
74 “specificity” hypothesis to establish whether any cognitive decline is specific to schizophrenia 
75 or common to other psychoses by examining cognitive change in individuals with psychotic 




80 Data were derived from the Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
81 (AESOP) study, a population-based, case-control study of first-episode psychosis. AESOP 
82 was approved by local research ethics committees and each participant gave written 
83 informed consent after receiving a complete description of the study. The study identified all 
84 first-episode psychosis cases (ICD-10: F10–F29 and F30–F33) aged 16 to 65 years 
85 presenting to specialist mental health services in tightly defined catchment areas of the 
86 United Kingdom (southeast London, Nottingham and Bristol) between September 1997 and 
87 August 2000. All potential cases making contact with psychiatric services (including adult 
88 community mental health teams, inpatient units, forensic services, learning disability 
89 services, adolescent mental health services, and drug and alcohol units) for the first time 
90 were screened. Exclusion criteria were previous contact with health services for psychosis, 
91 organic causes of psychotic symptoms, transient psychotic symptoms as the result of acute 
692 intoxication (as defined by ICD-10), and IQ<50. A random sample of control subjects with no 
93 past or present psychotic disorder were recruited using a sampling method that matched 
94 cases and controls by area of residence. Hereafter, data collected at this phase of the 
95 AESOP study is referred to as ‘baseline’. 
96 At baseline, detailed information was collected to enable patients to be traced, re-contacted 
97 and re-interviewed approximately 10 years later (‘follow-up’). At follow-up, patients currently 
98 in contact with mental health services were invited to participate through their clinical teams. 
99 Letters of invitation were sent to last known addresses of those not in contact with services. 
100 Non-responders were sent a second letter two to three weeks later. If patients were thought 
101 to have moved, contact was sought through their GP. Control subjects also provided contact 
102 details at baseline. Letters of invitation were sent and were followed-up with phone calls if no 
103 reply had been received within 2 weeks. If no reply had been received after 4 weeks, or 
104 where telephone numbers could not be obtained, in-person visits were made to the subject’s 
105 address.  A detailed overview of the AESOP study design and methods, as well as the 
106 follow-up has been published elsewhere (20, 21).
107 Analytic Cohort
108 Derivation of the sample included in the present analysis is illustrated in Figure 1. The 
109 analytic cohort consisted of healthy comparison subjects and subjects who had a consensus 
110 ICD-10 diagnosis at last follow-up of schizophrenia (F20), bipolar disorder or mania (F30.2, 
111 F31.2, F31.5), depressive psychoses (F32.3, F33.3) or other psychotic disorders including 
112 persistent delusional disorders and psychosis NOS (F22, F23, F28, F29). Both case and 
113 comparison subjects were required to be native English speakers or to have migrated to the 
114 UK by age 11. The latter ensured that all participants had a good command of English, even 
115 as a non-native language, by verifying that participants had completed at least their 
116 secondary education in the UK. Thus, this minimized the effect of linguistic or cultural biases 
117 on cognitive performance in a multiethnic sample. 
118 Figure 1. Derivation of first-episode psychosis patients and healthy comparison 
119 subjects from the Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
120 (AESOP) Project Baseline and 10-Year Follow Up.
121
122 Neuropsychological assessment
123 At baseline and follow-up, participants underwent cognitive testing with a neuropsychological 
124 battery, which assessed general intellectual ability (IQ), as well as specific cognitive 
7125 functions. Administration and scoring followed standard procedures. Full-scale IQ was 
126 estimated using the vocabulary, comprehension, digit symbol coding and block design 
127 subtests of the WAIS-R (22). Short forms of the WAIS-R have been shown to produce 
128 accurate estimates of full-scale IQ (23, 24). Specific functions were assessed using the 
129 following neuropsychological tests: Memory using the Rey Auditory-Verbal-Learning Test 
130 (RAVLT) trials 1 to 7  (learning, immediate and delayed verbal recall) (25), and the Visual 
131 Reproduction subtest of the Wechsler Memory Scale - Revised (WMS-R) (26); Verbal 
132 knowledge using the Vocabulary and Comprehension subtests of the WAIS-R (22); 
133 Processing speed using the WAIS-R digit symbol coding and the Trails-Making-Test Part A 
134 (27); Executive function/working memory using Trails-Making-Test - Part B (27), and Letter-
135 Number Span (28); Language using Category (semantic) and Letter Fluency (categories: 
136 ‘body parts’; ‘fruits’; ‘animals’, letters: F; A; S) (29), and Visuospatial ability using the WAIS-R 
137 Block Design subtest.
138 Diagnostic Assessment 
139 Clinical data were collected using the Schedules for Clinical Assessment in Neuropsychiatry 
140 (SCAN)(30). The SCAN incorporates the Present State Examination, Version 10, to elicit 
141 symptom-related data at time of presentation. Ratings on the SCAN are based on clinical 
142 interview, case note review, and information from informants (e.g. health professionals, close 
143 relatives). Researchers were trained on the SCAN with a World Health Organization-
144 approved course and reliability was established prior to commencement of the study using 
145 independent ratings of videotaped interviews. Rater agreement was evaluated using Kappa 
146 statistics, which ranged from 1.0 for psychosis as a category to between 0.6 and 0.8 for 
147 individual diagnoses. ICD-10 diagnoses were determined using SCAN data through 
148 consensus meetings with one of the PIs and other team members. Symptom severity was 
149 classified based on the SCAN Symptom Severity Rating Scale 2 as: 0 = Absent, 1 = Mild, 2 
150 = Moderate and 3 = Severe (21).
151 Covariates and medication information
152 Age was collected at baseline and follow-up. Sex, ethnicity, and level of education were 
153 collected at baseline. Treatment history with typical and/or atypical antipsychotic medication 
154 was ascertained for all patients from interview data and record review at follow-up. 
155 Creating Norms for Neuropsychological Tests
8156 A regression-based approach was used to create normative standards for the 
157 neuropsychological tests. Age at assessment, sex, ethnicity, and education were regressed 
158 on each of the neuropsychological measures in the healthy comparison sample at baseline 
159 and follow-up. Next, scores were adjusted on the basis of the regression results, and 
160 standard scores (i.e., z-scores) were created. The same adjustment and standardization 
161 procedure were applied to the patient groups, using the normative standards from the 
162 healthy comparison group.
163 Statistical analysis
164 Demographic and clinical characteristics of the baseline and follow-up cohorts were 
165 compared using summary statistics. For descriptive purposes, we compared patients with 
166 schizophrenia or other psychoses (including bipolar disorder, mania, depressive psychoses 
167 and other psychotic disorders) to the comparison group on normative-adjusted IQ and 
168 specific neuropsychological tests at baseline and follow-up using analysis of variance 
169 (ANOVA) models. 
170 To examine the “IQ decline” “generalized decline” and “specificity” hypotheses, we 
171 compared the schizophrenia and other psychoses groups to the comparison group on 
172 change in normative-adjusted IQ and specific neuropsychological tests from baseline to 
173 follow-up. Change scores were calculated by subtracting follow-up test scores from baseline 
174 test scores, so that positive scores indicate cognitive amelioration and negative scores 
175 indicate cognitive decline. ANCOVA models with planned orthogonal comparisons of each 
176 psychosis group to the comparison group, adjusting for time from baseline assessment and 
177 baseline test score were used. Adjustment for baseline performance is common in studies 
178 on cognitive change (31, 32).  For the “IQ decline” hypothesis, the significance level was set 
179 at p=0.05 (two-sided). For the “generalized decline” hypothesis, the significance level was 
180 set at a Bonferroni-corrected level of 0.0038 (0.05/13). All analyses were conducted using 
181 IBM SPSS Statistics version 24.
182
183 Results
184 Demographic characteristics of the baseline cohort and the cohort assessed at follow-up are 
185 presented in Table 1. Follow-up neuropsychological assessments were completed on 106 
186 patients (63 males), and 103 comparison subjects (40 males). Average follow-up duration 
187 was 109.3 months (SD=29.5) for patients and 102.9 (SD=34.1) for comparisons. Overall, the 
188 patients and comparisons assessed at follow-up were similar to the respective patients and 
9189 comparisons assessed at baseline in terms of demographic variables, suggesting that the 
190 cohort at follow-up was representative of the original cohort.
191 Cognitive impairment in schizophrenia and other psychoses at baseline and follow-up
192 As we have previously shown in the AESOP study cohort (19), patients with schizophrenia 
193 and patients with other psychoses showed deficits in IQ and individual neuropsychological 
194 tests at baseline. Figure 2 illustrates that that schizophrenia patients exhibited widespread, 
195 persistent, cognitive impairment, performing significantly worse than comparison subjects at 
196 both baseline and follow-up on 11 out of the 14 measures. Patients with other psychoses 
197 also showed widespread impairments, but these were generally of smaller magnitude than 
198 schizophrenia patients (Figure 2). (sTable2 presents the non-adjusted performance in IQ 
199 and specific neuropsychological tests at baseline and follow-up)
200 Figure 2. Neuropsychological Performance Among Patients with Schizophrenia 
201 and Other Psychoses at Baseline and Follow-Upa. 
202
203 a - Effect sizes (expressed in standardized [z] scores) and 95% Confidence Intervals 
204 (95%CI) of difference from comparison subjects at baseline and follow up. 
205 Comparison subjects set to zero (dotted line). Effect sizes are adjusted for age, 
206 sex, ethnicity, and level of education. 95% CI that do not include zero indicate 
207 statistical significance level p<0.05. Trailmaking A=Trail Making Test, Part A; 
208 Trailmaking B=Trail Making Test, Part B.
209
210 Cognitive change in schizophrenia and other psychoses
211 Next, we compared cognitive change over time in each of the psychoses groups 
212 (schizophrenia and other psychoses) to cognitive change in controls to test the “IQ decline”, 
213 “generalized decline” and “specificity” hypotheses. Figure 3 presents effect sizes of the 
214 difference in the within group change from baseline to follow-up in IQ and individual 
215 neuropsychological tests between the psychoses groups and controls. Effect sizes of 0.20, 
216 0.50, and 0.80 reflect small, medium, and large effects, respectively (33).
217 IQ decline hypothesis: IQ decline in the schizophrenia group was significantly larger than 
218 in controls, who showed no evidence of IQ decline. The IQ decline in the schizophrenia 
219 group compared to controls was of small magnitude (ES=-0.28, 95% Confidence Intervals: -
220 0.47 to -0.09, p=0.003), but was not attenuated when adjusting for education, ethnicity, sex, 
221 age-at-baseline assessment, or duration of follow-up, suggesting that IQ decline could not 
222 be attributed to these variables.
10
223 Generalized decline hypothesis: Compared to controls, the schizophrenia group showed a 
224 larger cognitive decline across tests in the memory and verbal knowledge domains (Figure 
225 3). In the memory domain, the schizophrenia group declines on verbal learning (p=0.001), 
226 immediate recall (p<0.00006), and delayed recall (p<0.00001) reached the Bonferroni-
227 corrected level of significance. In the verbal knowledge domain, decline on vocabulary 
228 (p=0.003) reached the Bonferroni-corrected level of significance. Compared to controls, the 
229 schizophrenia group showed no significant cognitive changes on Digit Symbol Coding and 
230 Trail-making-test Part A in the processing speed domain, Block Design in the visuospatial 
231 domain, and Trail-making-test Part B, Letter-Number Span, Letter Fluency and Category 
232 Fluency in the executive functions and working memory domain.
233 Specificity hypothesis: There was no evidence for IQ decline in the other psychoses group 
234 compared to controls (ES=-0.09, 95% Confidence Intervals: -0.30 to 0.11; p=0.37), (Figure 
235 3). In terms of cognitive domains, like the schizophrenia group, the other psychoses group 
236 showed larger declines than controls across test in the memory domain, with verbal learning 
237 (p=0.001) reaching the Bonferroni-corrected level of significance. Like schizophrenia 
238 patients, the other psychoses group showed static deficits in tests of processing speed, 
239 executive functions and working memory, and visuospatial ability (Figure 3). 
240 Figure 3. Change in Neuropsychological Performance Among Patients with 
241 Schizophrenia and Other Psychoses a, *. 
242
243 a - Presented are effect sizes and 95% Confidence Intervals of difference in change 
244 from baseline to follow up between the diagnostic group and comparison group. 
245 95% Confidence Intervals that do not include zero indicate statistical significance 
246 level p<0.05. Effect sizes are adjusted for age, sex, ethnicity, level of education, 
247 time from baseline assessment and baseline test score. Trailmaking A=Trail Making 
248 Test, Part A; Trailmaking B=Trail Making Test, Part B.
249 * - Presents Bonferroni corrected level (p≤0.0038)   
250
251 Medication
252 We examined the potential moderating effect of antipsychotic medication on IQ decline in the 
253 schizophrenia group. There was no statistically significant difference in IQ decline (p=0.23) 
254 between patients with a history of treatment with typical antipsychotics only (45% of sample) 
255 and those with a history of treatment with both typical and atypical antipsychotics (55% of 
256 sample). Duration of antipsychotic medication (mean = 323±192 weeks) did not attenuate IQ 
257 decline in schizophrenia (F=7.30, p=0.008 vs. F=7.20, p=0.009 for ANCOVA models with vs. 
258 without duration of treatment as a covariate). 
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259 Symptom severity
260 Since illness severity might influence cognition, we also examined the association between 
261 baseline symptom severity and change in cognitive functioning, as well as change in 
262 symptom severity between baseline and follow up and change in cognitive functioning. 
263 Schizophrenia patients with severe symptoms at baseline showed statistically significantly 
264 greater cognitive decline than patients with mild or moderate symptoms across multiple tests 
265 in the memory domain (Figure 4). However, there was no association between change in 
266 symptom severity and change in cognitive functioning (sTable 2 and sFigure 1), and no 
267 evidence for a dose-response relationship across levels of severity (Figure 4). In the other 
268 psychoses group there was no evidence for an association between symptom severity, or 
269 change in symptom severity, and change in cognitive functioning (Figure 4, sFigure1).
270 Figure 4. Change in Neuropsychological Performance Among Patients With 
271 Schizophrenia and Other Psychoses in Relation to Symptom Severity at Baselinea
272 a - Presented are effect sizes and 95% Confidence Intervals of difference in change 
273 from baseline to follow up between the diagnostic group and comparison group as 
274 a function of symptom severity at baseline. 95% Confidence Intervals that do not 
275 include zero indicate statistical significance level p<0.05. Effect sizes are adjusted 
276 for age, sex, ethnicity, level of education, time from baseline assessment and 
277 baseline test score. Trailmaking A=Trail Making Test, Part A; Trailmaking B=Trail 
278 Making Test, Part B.
279
280 Sensitivity analyses
281 We also examined the potential impact of attrition by applying linear mixed models which 
282 permit varying numbers of measurements per person and time point, while adjusting for 
283 within-individual (i.e. between measures) variation. Similar results were obtained in models 
284 that included only cases and controls with data from both assessment time points, and in 
285 models that also included cases and controls with data from a single assessment, indicating 
286 results were not biased by attrition. 
287 As a further comparison, we examined IQ change in controls with lower IQ (IQ<90 at 
288 baseline, equal to 1SD below the control group mean, N=17, 16.5% of sample). These 
289 individuals are of interest because, like schizophrenia patients, they also exhibit lower IQ, 
290 and yet they did not develop psychosis. In contrast to patients with schizophrenia, individuals 
291 with lower IQ did not show evidence of IQ decline, neither in absolute terms nor relative to 
292 controls without a cognitive impairment since mean IQ at baseline was 84.9, and at follow up 




296 Using a population-based, case-control sample followed prospectively from the first 
297 psychotic episode we provide evidence for cognitive decline after illness onset in patients 
298 with schizophrenia. 
299 These findings advance knowledge in three important ways. First, the results lend support to 
300 the “IQ decline” hypothesis. As a group, schizophrenia patients showed IQ decline between 
301 baseline and follow up assessments, with an effect size of small magnitude (ES=0.28). This 
302 finding is in contrast with earlier studies reporting stabilization of cognitive deficits after the 
303 onset of psychosis (15). However, previous studies had important methodological limitations, 
304 including a short follow-up period of patients, and lack of a comparison group that is similarly 
305 followed-up. The finding of IQ decline is in line with findings from neuroimaging studies of 
306 greater age-associated brain volume loss (34), as well as deviated gyrification trajectories in 
307 schizophrenia patients in adulthood (35). Moreover, reduction in cortical volume has been 
308 associated with IQ decline in schizophrenia patients (36). 
309 Second, the current findings do not support the “generalized decline” hypothesis. Decline 
310 was not ubiquitous and varied across cognitive domains. The schizophrenia group exhibited 
311 declines in verbal knowledge and memory.  In contrast, processing speed, executive 
312 functions and visuospatial ability did not decline. These contrasts can be generally viewed as 
313 reflecting differences between the impact of the illness on crystalized (verbal knowledge) vs. 
314 fluid (processing speed, executive functions, visuospatial) abilities. Our findings of 
315 decreasing crystalized abilities and memory scores between baseline and follow-up is in line 
316 with previous evidence (37) and suggest that increasing deficits in these domains may 
317 reflect actual loss of ability, rather than abnormal cognitive development (i.e. “lag”) (16). 
318 Alternatively, our findings may reflect difficulties with the maintenance and acquisition of new 
319 verbal knowledge due to substantial and increasing memory deficits. While most cognitive 
320 abilities in the general population start to show stabilization or even decline in early 
321 adulthood, crystalized abilities may peak much later (38-40). In our study, measures of fluid 
322 abilities showed a large deficit already at the first episode, which remained static thereafter. 
323 While previous longitudinal epidemiological studies have shown cognitive decline in 
324 schizophrenia from the premorbid period in childhood to the chronic stage in mid-adulthood 
325 (8-10), they were unable to determine when this decline occurred. Our findings suggest that 
326 most of the decline in fluid abilities occurs before the first episode, while crystalized abilities 
13
327 may continue to decline after onset. Importantly, the decline in IQ after onset is likely to be 
328 due to the decline seen in crystallized abilities.  
329 Third, the current findings do not support the “specificity” hypothesis since patients with 
330 schizophrenia, but also other psychoses, experienced cognitive decline. However, while 
331 patients with schizophrenia showed decline in IQ, memory and verbal knowledge, patients 
332 with other psychoses showed decline only in certain memory functions. Moreover, in line 
333 with previous reports (41, 42), the other psychoses group showed an overall impairment 
334 profile that was qualitatively similar, yet quantitatively smaller than the schizophrenia group. 
335 Thus, our findings suggest that cognitive decline is not specific to schizophrenia, but also 
336 evident in other psychoses. However, large, widespread, cognitive decline may still be 
337 specific to schizophrenia, since the other psychoses group showed a smaller and less 
338 generalized cognitive decline.  Interestingly, there was no evidence of decline in a key 
339 comparison group, namely individuals with lower IQ who did not develop psychosis. This 
340 group may in fact experience a different process of regression-to-the-mean.
341 The current findings should be viewed in the context of certain limitations. First, although we 
342 found evidence for cognitive decline after illness onset, we could not fully map the course of 
343 deficits and cognitive functions may vary in the timing of decline following the first episode. 
344 Second, group sizes did not allow for an analysis of the heterogeneity of cognitive course 
345 and also limited our ability to investigate more specific diagnostic sub-groups, such as 
346 bipolar/mania. Third, we ruled out two explanations for the observed cognitive decline, 
347 namely, type or duration of antipsychotic treatment. Unfortunately, we did not have 
348 information to examine other potential moderators of cognitive decline, such as social 
349 isolation, smoking and illicit drug abuse, victimization, or physical health problems such as 
350 obesity, diabetes and hypertensions. Moreover, despite the fact that we adjusted for 
351 education in all our analyses, poor education in the schizophrenia group after the first 
352 psychotic episode could still partly explain some of the group differences. 
353 There is conflicting evidence regarding the relationship between change in symptoms and 
354 cognitive functioning (43, 44). In our study, change in severity of psychosis was only 
355 minimally associated with cognitive change. These results are consistent with cross-
356 sectional findings of only a weak association between positive symptoms and cognitive 
357 impairment (45). Longitudinal evidence also suggests a minimal association between 
358 change in positive as well as negative symptoms, and change in cognition (43, 44, 46). 
359 Interestingly, in our study, schizophrenia patients with severe symptoms at baseline showed 
360 greater cognitive decline than patients with mild or moderate symptoms. While this group 
361 was small (21% of overall group), the magnitude of decline in the memory domain was large. 
14
362 Thus, this finding points to a potential subgroup of schizophrenia patients that may greatly 
363 benefit from being specifically targeted for cognitive remediation.
364 Our findings have important implications for understanding the nature and course of 
365 cognitive impairment in schizophrenia, as well as other psychoses. Integrating the current 
366 findings with those of previous studies (16) suggests that cognitive dysfunction in 
367 schizophrenia may result from a complex interplay between an early, static neuropathology 
368 (47, 48) and dynamic age-related processes (49, 50). As such, cognitive functions that 
369 develop and peak relatively early in life, such as processing speed and visuospatial abilities 
370 (39) may show aberrant development, resulting in slowed growth prior to the onset of 
371 schizophrenia (16), but relative stabilization throughout the illness course. On the other 
372 hand, cognitive functions that continue to evolve through adult life, such as language (39), 
373 may show further deterioration throughout the course of schizophrenia. Finally, functions 
374 sensitive to age-related cognitive decline, such as memory, may begin to decline in middle 
375 adulthood before normative aging becomes apparent (40). 
376 In conclusion, the present study demonstrates that while a substantial proportion of the 
377 cognitive impairment seen in adult patients with schizophrenia, as well as other psychoses, 
378 is present already at the first episode, these patients continue to experience cognitive 
379 decline after illness onset. However, the nature of this decline varies across 
380 neuropsychological functions. While large deficits in processing speed are already apparent 
381 at the first episode, deficits in verbal knowledge and memory continue to increase. These 
382 findings suggest that different pathophysiological mechanisms may underlie individual 
383 neuropsychological deficits seen in adult psychosis patients. Future research should 
384 determine which of these are consequent upon the illness itself, and which on the 
385 psychosocial factors patients experience. Finally, these findings highlight the importance of 
386 targeting early developmental stages in future studies of the causes of cognitive deficits 
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